|Bid||17.32 x 5800|
|Ask||17.33 x 800|
|Day's Range||17.20 - 17.42|
|52 Week Range||15.22 - 50.57|
|PE Ratio (TTM)||-2.83|
|Dividend & Yield||1.10 (6.43%)|
|1y Target Est||N/A|
Biopharma companies are using court battles and reformulations to prevent generic-drug makers from capturing sales.
Long-term investors take note, because bargains abound.
Everyone knows high prescription drug prices are a problem, but except for pharma stockholders, few people may realize that price cuts are rippling through the generic side of the industry.